The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling
| Autor: | Denis Vinatier, Robert Day, Rémi Longuespée, Annie Desmons, Olivier Kerdraon, Isabelle Fournier, Charlotte Boyon, Michel Salzet, Amélie Jacquet, Céline Castellier |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
MALDI imaging
Proteasome Endopeptidase Complex Pathology medicine.medical_specialty Histology medicine.medical_treatment Muscle Proteins 03 medical and health sciences 0302 clinical medicine Biomarkers Tumor medicine Humans Proteasome activator complex Molecular Biology Cellular localization 030304 developmental biology Ovarian Neoplasms 0303 health sciences Chemotherapy Chemistry Carcinoma Cell Biology medicine.disease Immunohistochemistry 3. Good health Medical Laboratory Technology Specific antibody Serous fluid Early Diagnosis Spectrometry Mass Matrix-Assisted Laser Desorption-Ionization 030220 oncology & carcinogenesis Female Neoplasm Recurrence Local Ovarian cancer |
| Zdroj: | Histochemistry and Cell Biology. 138:141-154 |
| ISSN: | 1432-119X 0948-6143 |
| DOI: | 10.1007/s00418-012-0953-0 |
| Popis: | This study reports on the C-terminal fragment of the 11S proteasome activator complex (PA28 or Reg alpha), a novel ovarian-specific biomarker of early and late stages of ovarian cancer (OVC) relapse, in patient biopsies after chemotherapy. A total of 179 tissue samples were analyzed: 8 stage I, 55 stage III–IV, 10 relapsed serous carcinomas, 25 mucinous carcinomas and 12 borderline and 68 benign ovarian tissue samples. This fragment was detected by MALDI mass spectrometry profiling in conjunction with a novel extraction method using hexafluoroisopropanol (1,1,1,3,3,3-hexafluoro-2-propanol; HFIP) solvents for protein solubilization and by immunohistochemistry using a specific antibody directed against the C-terminal fragment of PA28. Due to its specific cellular localization, this fragment is a suitable candidate for early OVC diagnosis, patient prognosis and follow-up during therapy and discriminating borderline cancers. Statistical analyses performed for this marker at different OVC stages reflect a prevalence of 77.66 ± 8.77 % (with a correlation coefficient value p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|